State-of-the-art Manufacturing Facility

In order to control all aspects of Midatech’s GNP platform and its development, the company established a state-of-the-art manufacturing facility near Bilbao, Spain. This cGMP site has sufficient capacity for manufacturing clinical trial materials. The process is engineered to be easily scalable and so capacity can be expanded quickly if needed for larger trials and potential subsequent sales.

Manufacture of sterile injectables for human studies

In order to be in the position to clinically test and evaluate candidate GNP-based cancer vaccines and GNP-chemotherapeutics, which are administered by intravenous injection, clinical candidate compounds have to be produced under sterile conditions. To that end, Midatech’s manufacturing unit has started the process of adapting its infrastructure by integrating a separate steriles production unit within the GMP manufacturing containment area. Once completed accreditation by the relevant regulatory bodies will be sought.